CFTR MODULATOR THERAPY FOR THE 'REMAINING 10%': COMBINATION POTENTIATOR ('CO-POTENTIATOR') THERAPY FOR CFTR MUTANTS THAT ARE POORLY RESPONSIVE TO SINGLE POTENTIATORS, INCLUDING W1282X AND N1303K

Phuan P.; Son J.; Tan J. T.; Li C.; Musante I; Zlock L.; Nielson D. W.; Finkbeiner W.; Kurth M.; Galietta L. J.; Haggie P. M.; Verkman A. S.

首页> 外文期刊>Pediatric Pulmonology >CFTR MODULATOR THERAPY FOR THE 'REMAINING 10%': COMBINATION POTENTIATOR ('CO-POTENTIATOR') THERAPY FOR CFTR MUTANTS THAT ARE POORLY RESPONSIVE TO SINGLE POTENTIATORS, INCLUDING W1282X AND N1303K

【24h】

CFTR MODULATOR THERAPY FOR THE 'REMAINING 10%': COMBINATION POTENTIATOR ('CO-POTENTIATOR') THERAPY FOR CFTR MUTANTS THAT ARE POORLY RESPONSIVE TO SINGLE POTENTIATORS, INCLUDING W1282X AND N1303K

机译：CFTR调节剂治疗用于“剩余10％”：CFTR突变体的组合电压蛋白（“共调高器”）对单次增强剂敏捷，包括W1282X和N1303K

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Pediatric Pulmonology》 |2018年第2期|共1页
作者
Phuan P.; Son J.; Tan J. T.; Li C.; Musante I; Zlock L.; Nielson D. W.; Finkbeiner W.; Kurth M.; Galietta L. J.; Haggie P. M.; Verkman A. S.;
展开▼
作者单位

UCSF Div Nephrol San Francisco CA USA;

UCDavis Chem Davis CA USA;

UCSF Div Nephrol San Francisco CA USA;

UCDavis Chem Davis CA USA;

TIGEM Pozzuoli Italy;

UCSF Pathol San Francisco CA USA;

UCSF Pediat San Francisco CA USA;

UCSF Pathol San Francisco CA USA;

UCDavis Chem Davis CA USA;

TIGEM Pozzuoli Italy;

UCSF Div Nephrol San Francisco CA USA;

UCSF Div Nephrol San Francisco CA USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类儿科学;
关键词

相似文献

外文文献
专利

1. CFTR MODULATOR THERAPY FOR THE "REMAINING 10%": COMBINATION POTENTIATOR ("CO-POTENTIATOR") THERAPY FOR CFTR MUTANTS THAT ARE POORLY RESPONSIVE TO SINGLE POTENTIATORS, INCLUDING W1282X AND N1303K [J] . Phuan P., Son J., Tan J. T., Pediatric Pulmonology . 2018,第Suppla2期

机译：CFTR调节剂治疗用于“剩余10％”：CFTR突变体的组合电压蛋白（“共调高器”）对单次增强剂敏捷，包括W1282X和N1303K
2. Combination potentiator (‘co-potentiator’) therapy for CF caused by CFTR mutants, including N1303K, that are poorly responsive to single potentiators [J] . Puay-Wah Phuan, Jung-Ho Son, Joseph-Anthony Tan, Journal of cystic fibrosis: official journal of the European Cystic Fibrosis Society . 2018,第5期

机译：CF突变体（包括N1303K）引起的CF引起的组合电压毒剂（“共调高器”治疗，对单个增强剂令人难以响应
3. Combination potentiator (‘co-potentiator’) therapy for CF caused by CFTR mutants, including N1303K, that are poorly responsive to single potentiators [J] . Dennis W. Nielson, Walter E. Finkbeiner, Mark J. Kurth, Lancet Neurology . 2018,第5期

机译：CF突变体（包括N1303K）引起的CF引起的组合电压毒剂（“共调高器”治疗，对单个增强剂令人难以响应
4. COMBINATION POTENTIATOR (‘CO-POTENTIATOR’) THERAPY FOR CF CAUSED BY CFTR MUTANTS INCLUDING N1303K THAT ARE POORLY RESPONSIVE TO SINGLE POTENTIATORS [O] . Puay-Wah Phuan, Jung-Ho Son, Joseph-Anthony Tan, -1

机译：CFTR突变体对CF进行的复合增效剂（ CO-POTENTIATOR）治疗包括N1303K对单增效剂反应不良
5. WS7.3 VX-661, an investigational CFTR corrector, in combination with ivacaftor, a CFTR potentiator, in patients with CF and homozygous for the F508Del-CFTR mutation: Interim analysis [O] . Donaldson S., Pilewski J., Griese M., 2013

机译：WS7.3 VX-661，研究性CFTR校正剂，与ivacaftor（CFTR增强剂）组合，用于CF和F508Del-CFTR突变纯合子患者：中期分析

CFTR MODULATOR THERAPY FOR THE 'REMAINING 10%': COMBINATION POTENTIATOR ('CO-POTENTIATOR') THERAPY FOR CFTR MUTANTS THAT ARE POORLY RESPONSIVE TO SINGLE POTENTIATORS, INCLUDING W1282X AND N1303K

著录项

相似文献

相关主题

期刊订阅